Alamar Biosciences, Inc. ALMR
31.84 USD +3.79 (+13.51%)
At closeNov 9, 2026, 4:01 PM EST
31.84 0.00 0.00%
After hours · Nov 9, 4:01 PM ET
28.39 Day range 31.98
18.85 52-week range 39.61
- YTD
- +44.73%
- 1 year
- +44.73%
News
defenseworld.net Alamar Biosciences (NASDAQ:ALMR) Stock: Insider Corporate Gp Vi Ltd. Qiming Sells 111,313 Shares Alamar Biosciences, Inc. (NASDAQ: ALMR - Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 111,313 shares of the firm's stock in a transaction on Tuesday, November 3rd. The stock…
globenewswire.com Alamar Biosciences to Participate in Upcoming Investor Conferences Fremont, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced…
benzinga.com TD Cowen Maintains Buy on Alamar Biosciences, Raises Price Target to $36 TD Cowen analyst Dan Brennan maintains Alamar Biosciences (NASDAQ:ALMR) with a Buy and raises the price target from $34 to $36.
seekingalpha.com Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript Alamar Biosciences, Inc. (ALMR) Q3 2026 Earnings Call Transcript
marketbeat.com Alamar Biosciences Q3 Earnings Call Highlights Alamar Biosciences NASDAQ: ALMR reported third-quarter revenue growth of 68% year over year, driven by rising consumables sales, new instrument placements and its largest Technology Access Program,…
zacks.com Alamar (ALMR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Alamar (ALMR) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
benzinga.com Alamar Biosciences Q3 2026 Earnings Call Transcript Alamar Biosciences (NASDAQ:ALMR) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Alamar Biosciences Raises FY2026 Sales Guidance from $116.000M-$120.000M to $121.000M-$123.000M vs $118.632M Est Alamar Biosciences (NASDAQ:ALMR) raises FY2026 sales outlook from $116.000 million-$120.000 million to $121.000 million-$123.000 million vs $118.632 million estimate.
benzinga.com Alamar Biosciences Q3 EPS $(0.19); Sales $33.55M Up 68% From $19.91M YoY Alamar Biosciences (NASDAQ:ALMR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. The company reported quarterly sales of $33.550…
benzinga.com Alamar Biosciences Partners With GSK For Its Use Of NULISA Platform In Trial To Evaluate Protein Signatures Regarding Disease Progression, Biological Subtypes And Treatment Response Across Respiratory, Liver, Kidney, Neurological And Autoimmune Conditions Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a strategic scientific collaboration with GSK plc…
globenewswire.com Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today reported…
globenewswire.com Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a…
globenewswire.com UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study Supported The Michael J Fox Foundation for Parkinson's Research, Alzheimer's Research UK and LifeArc, the study targets earlier detection, prevention and treatment of Parkinson's disease, Alzheimer's…
globenewswire.com Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study FREMONT, Calif. and HELSINKI, Finland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR) and Nightingale Health Plc (Nasdaq Helsinki: HEALTH, OTCQX: NHLTY, NGHLF) today…
benzinga.com Mistras Group, Strategy, Hyperliquid Strategies And Other Big Stocks Moving Higher On Friday U.S. stocks were mixed as the Dow fell 150 points; Mistras surged on a $20.35/share buyout deal, while crypto and tech stocks gained.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million. Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4%…
benzinga.com Top 3 Health Care Stocks That May Implode In August 3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
benzinga.com Stifel Maintains Buy on Alamar Biosciences, Raises Price Target to $32 Stifel analyst Daniel Arias maintains Alamar Biosciences (NASDAQ:ALMR) with a Buy and raises the price target from $28 to $32.
benzinga.com Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum Alamar Biosciences expands its Alzheimer’s data partnership, adds 86,000 samples and reports Q2 sales growth of 82% year-over-year.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
- benzinga.com JP Morgan Maintains Overweight on Alamar Biosciences, Raises Price Target to $35 JP Morgan analyst Casey Woodring maintains Alamar Biosciences (NASDAQ:ALMR) with a Overweight and raises the price target from $32 to $35.
benzinga.com Quantum, Kopin, Alamar Biosciences And Other Big Stocks Moving Higher On Tuesday QMCO gained 44% after reporting strong Q1 earnings and guidance above estimates. Other gainers include NIQ, RPD, KOPN, FRMI, ALMR, MG, BW, SE, RNW, and RIOT.
benzinga.com Alamar Biosciences Sees FY2026 Sales $116.000M-$120.000M vs $113.259M Est Alamar Biosciences (NASDAQ:ALMR) sees FY2026 sales of $116.000 million-$120.000 million vs $113.259 million analyst estimate.- benzinga.com Alamar Biosciences Launches NULISAseq Immune 340 Panel, Broadest Multiplexed Immune Profiling Solution Available For Translational Research And Drug Development Alamar Biosciences, Inc. (NASDAQ:ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced the launch of the NULISAseq™ Immune 340 Panel, its…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market Session US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results. Other stocks declining in pre-market trading.
benzinga.com Why Friedman Industries Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket Friedman Industries Inc (NASDAQ: FRD) rose in pre-market trading after posting strong Q4 earnings. Other gainers include BYAH, VSME, ADTX, EDHL, GMM, HKIT, RKTO, ASYS, and PWRL. Losers include GELS,…
benzinga.com This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts change outlook on top names. Check their ratings & price targets for AVEX, ALMR, TNDM, SWX, KLRA. See what they think of SWX stock.